Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2013

View Archived Issues

Large-scale studies link new genes to obesity

Soligenix and Intrexon enter exclusive worldwide collaboration for melioidosis

Nucleocapsid assembly effector with efficacy in reducing viral cccDNA in vitro

Genmab reports phase II data for ofatumumab combined with bendamustine

Ferring Pharmaceuticals begins two phase III trials of elobixibat

Abide Therapeutics and Merck & Co. form collaboration

GSK-1322322 shows activity against Legionella pneumophila

Gilead to commence third phase III trial of fixed-dose combination tablet for HCV infection

Acceleron and Shire decide to conclude collaboration on ACE-031

RNL BIO files IND to commence phase II trial of RNL-JointStem for osteoarthritis

Pharmacodynamics of GS-9620 tested in chronic HCV patients

Takeda presents novel CENP-E inhibitor with oncolytic activity

DM-CHOC-PEN well tolerated in phase I trial

Shionogi & Co. discloses new HIV integrase inhibitors

Novel FGFR inhibitors patented by Orion Corp.

Beta Pharma synthesizes new agents for cancer

Fibrocell Science begins phase II trial of azficel-T in new indication

CSIR discloses novel agents for bacterial infections

Lundbeck prepares new PDE9 inhibitors for neurodegenerative disorders

Bristol-Myers Squibb divulges novel NS5B inhibitors

Regeneron expands ophthalmology pipeline

Pharmaco-Kinesis reports development of combinatorial nano-drug for gliomas and other cancers

Ambrx and Bristol-Myers Squibb form new collaboration for antibody-drug conjugates

FDA expands approval of efavirenz to patients as young as 3 months

Merck & Co. gains FDA approval for Liptruzet combination tablet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...